APA (7th ed.) Citation

RM, S., RB, J., U, S., S, B., M, N., R, A., . . . PA, M. (2023). Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: An international randomised controlled trial. Annals of the rheumatic diseases, 82(7), 937. https://doi.org/10.1136/ard-2022-223559

Chicago Style (17th ed.) Citation

RM, Smith, et al. "Rituximab Versus Azathioprine for Maintenance of Remission for Patients with ANCA-associated Vasculitis and Relapsing Disease: An International Randomised Controlled Trial." Annals of the Rheumatic Diseases 82, no. 7 (2023): 937. https://doi.org/10.1136/ard-2022-223559.

MLA (9th ed.) Citation

RM, Smith, et al. "Rituximab Versus Azathioprine for Maintenance of Remission for Patients with ANCA-associated Vasculitis and Relapsing Disease: An International Randomised Controlled Trial." Annals of the Rheumatic Diseases, vol. 82, no. 7, 2023, p. 937, https://doi.org/10.1136/ard-2022-223559.